The treatment of essential hypertension is based essentially on non-pharmacological recommendations and on the prescription of blood pressure lowering drugs and/or diuretics. Because of the silent nature of hypertension, long-term adherence to therapy is one of the major issues of the management of hypertensive therapy. Indeed, it is well recognized that many patients interrupt their antihypertensive treatment completely after 1 year, and this lack of persistence has a major impact on our ability to control blood pressure in the hypertensive population. Today, there are multiple ways of assessing drug adherence in patients, but only very few of them are accurate, and the most accurate ones are difficult to implement in clinical practice. Thus, physicians have no real capacity to establish a correct diagnosis of nonpersistence or poor adherence even in high-risk patients such as patients with resistant hypertension. Therefore, there is an urgent need to develop new techniques or devices to help physicians in their ability to handle adherence to therapy and to improve blood pressure control in the population.


Persistence Electronic monitoring Drug measurements Resistant hypertension Multidiscipline Healthcare system 


  1. 1.
    2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31(10): 1925–38.Google Scholar
  2. 2.
    James PA, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMedGoogle Scholar
  3. 3.
    National Clinical Guideline Centre. National Institute for Health and Clinical Excellence: Guidance. In: Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. London: Royal College of Physicians (UK) National Clinical Guideline Centre; 2011.Google Scholar
  4. 4.
    Kearney PM, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Benetos A, et al. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens. 2003;21(9):1635–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Mancia G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril study. Hypertension. 2007;50(2):299–305.CrossRefPubMedGoogle Scholar
  7. 7.
    Burnier M. Blood pressure control and the implementation of guidelines in clinical practice: can we fill the gap? J Hypertens. 2002;20(7):1251–3.CrossRefPubMedGoogle Scholar
  8. 8.
    Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7.e1.CrossRefPubMedGoogle Scholar
  9. 9.
    Vrijens B, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Blaschke TF, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275–301.CrossRefPubMedGoogle Scholar
  11. 11.
    Vrijens B, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Morisky DE, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–54.CrossRefGoogle Scholar
  13. 13.
    Halpern MT, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039–48.CrossRefPubMedGoogle Scholar
  14. 14.
    Hasselstrom J, et al. The Swedish Primary Care Cardiovascular Database (SPCCD): 74 751 hypertensive primary care patients. Blood Press. 2014;23(2):116–25.CrossRefPubMedGoogle Scholar
  15. 15.
    Qvarnstrom M, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013;69(11):1955–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Jung O, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Tomaszewski M, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–61.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Strauch B, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Burnier M, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–25.CrossRefPubMedGoogle Scholar
  21. 21.
    Simpson SH, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Granger BB, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366(9502):2005–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Krousel-Wood MA, et al. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93(3):753–69.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Maimaris W, et al. The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med. 2013;10(7):e1001490.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens. 2009;27(8):1540–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Wetzels GE, et al. Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens. 2007;20(2):119–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract. 2011;65(2):127–33.CrossRefPubMedGoogle Scholar
  28. 28.
    Mallion JM, et al. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens Suppl. 1998;16(1):S75–9.PubMedGoogle Scholar
  29. 29.
    Bramley TJ, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239–45.PubMedGoogle Scholar
  30. 30.
    Corrao G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Perreault S, et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69(1):74–84.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Perreault S, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266(2):207–18.CrossRefPubMedGoogle Scholar
  33. 33.
    Kettani FZ, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213–20.CrossRefPubMedGoogle Scholar
  34. 34.
    Kumar N, Calhoun DA, Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013;6:139–51.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Burnier M. Managing ‘resistance’: is adherence a target for treatment? Curr Opin Nephrol Hypertens. 2014;23(5):439–43.CrossRefPubMedGoogle Scholar
  36. 36.
    de la Sierra A, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.CrossRefPubMedGoogle Scholar
  37. 37.
    Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57(6):1076–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Persu A, et al. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension. 2014;63(6):1319–25.CrossRefPubMedGoogle Scholar
  39. 39.
    Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463–8.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Burnier M, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens. 2001;19(2):335–41.CrossRefPubMedGoogle Scholar
  41. 41.
    Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150(7):1377–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Smith SM, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635–43.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Fadl Elmula FE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63(5):991–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Bunker J, et al. How common is true resistant hypertension? J Hum Hypertens. 2011;25(2):137–40.CrossRefPubMedGoogle Scholar
  45. 45.
    Gwadry-Sridhar FH, et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health. 2013;16(5):863–71.CrossRefPubMedGoogle Scholar
  46. 46.
    McManus RJ, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312(8):799–808.CrossRefPubMedGoogle Scholar
  47. 47.
    Parati G, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24(12):779–85.CrossRefPubMedGoogle Scholar
  48. 48.
    Marquez-Contreras E, et al. Non-compliance and inertia in hypertensive Spaniards at high cardiovascular risk: CUMPLE study. Curr Med Res Opin. 2014;30(1):11–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Coleman CI, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–39.PubMedGoogle Scholar
  50. 50.
    Iskedjian M, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24(2):302–16.CrossRefPubMedGoogle Scholar
  51. 51.
    Burnier M, et al. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract. 2009;63(5):790–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Castellano JM, et al. A polypill strategy to improve adherence: results from FOCUS (fixed-dose combination drug for secondary cardiovascular prevention) project. J Am Coll Cardiol. 2014;64:2071.CrossRefPubMedGoogle Scholar
  54. 54.
    Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.CrossRefPubMedGoogle Scholar
  55. 55.
    Selak V, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.CrossRefPubMedGoogle Scholar
  56. 56.
    Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;(2):CD004804.Google Scholar
  57. 57.
    Neri L, et al. Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol. 2011;34(1):71–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Lowy A, et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract. 2011;65(1):41–53.CrossRefPubMedGoogle Scholar
  59. 59.
    Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003;60(7):657–65.PubMedGoogle Scholar
  60. 60.
    Brunenberg DE, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics. 2007;25(3):239–51.CrossRefPubMedGoogle Scholar
  61. 61.
    Omboni S, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31(3):455–67; discussion 467–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Schneider MP, Burnier M. On-line home monitoring of drug compliance: is it feasible? Eur J Clin Pharmacol. 1998;54(6):489–90.CrossRefPubMedGoogle Scholar
  63. 63.
    Santschi V, et al. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med. 2008;19(6):427–34.CrossRefPubMedGoogle Scholar
  64. 64.
    Santschi V, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718.CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Van Zuilen AD, et al. MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol. 2008;21(3):261–7.PubMedGoogle Scholar
  66. 66.
    Chapman RH, et al. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*. Int J Clin Pract. 2010;64(2):169–81.CrossRefPubMedGoogle Scholar
  67. 67.
    Levi F, et al. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002;88(2):119–24.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Service of Nephrology and Hypertension, Department of MedicineCentre Hospitalier Universitaire Vaudois (CHUV)LausanneSwitzerland

Personalised recommendations